SBS possesses a repressive property on hepatic steatosis, which is associated with inhibition of SREBP1c, PPARγ, ACC, DGAT2, and FAS, and induction of PPARα, suggesting a potential application of SBS in treatment of HFD-induced NAFLD. This evidence concerns the gene SREBF1 and metabolic dysfunction-associated steatotic liver disease.